Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...

Read Also: Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts? Cantor Fitzgerald analyst C.J.

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.